Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12585MR)

This product GTTS-WQ12585MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12585MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9455MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ71MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ15163MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA T1h
GTTS-WQ4851MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ14259MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ11690MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ3759MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ1447MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACC-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW